BridgeBio Oncology Therapeutics, Inc.
BBOT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.66
KIRA · Stoqly’s AI analyst, in plain words
- BridgeBio Oncology Therapeutics, Inc. lost $134M in fiscal 2025.
- Free cash flow was −$115M in fiscal 2025, — of revenue.
Market cap
$213M
P/E
—
Revenue
—
Net income
−$134M
Free cash flow
−$115M
Operating margin
—
BridgeBio Oncology Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$134M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What BridgeBio Oncology Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- 0001869105
BridgeBio Oncology Therapeutics, Inc. · BBOT
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$0.0M | −$74.3M | −$134M |
| Diluted EPS | — | −$5,756.41 | −$4.30 |
| Cash | |||
| Cash from operations | — | −$55.0M | −$114M |
| Capital expenditure | — | $0.0M | $0.6M |
| Free cash flow | — | −$55.1M | −$115M |
| Share count change | — | — | 241,332.6% |
| Debt and strength | |||
| Cash and short-term investments | $0.3M | $156M | $425M |
| Shareholders' equity | −$116M | −$179M | $411M |
| Current ratio | — | 8.1x | 12.3x |
| Returns and quality | |||
| Return on equity | — | — | −115.3% |
| Return on tangible equity | — | — | −32.6% |
| Altman Z'' | — | −11.7 | 12.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BridgeBio Oncology Therapeutics, Inc. · BBOT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.66 a share, the company is worth $213M.
Source: SEC EDGAR XBRL filings (CIK 0001869105). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.